Treating Cancer-Related Depression

LISA SCHULMEISTER, MN, RN, ACNS-BC, OCN, FAAN
Monday, July 14, 2014
Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Dartmouth researchers searched Medline, the Cochrane Library, the Cumulative Index to Nursing and Allied Health Literature, a clinical trials database, and meeting abstracts to conduct a meta-analysis of studies that examined the pharmacologic treatment of cancer-related depression. Included in the analysis were randomized trials comparing antidepressants to placebos or no treatment.

The review identified two classes of antidepressants that reduce symptoms of depression, the alpha-2-adrenergic receptor antagonist Mianserin (not available in the United States) and the selective serotonin reuptake inhibitors fluoxetine (Prozac) and paroxetine (Paxil).  Miaserin had a higher depression response rate compared to placebos. Paroxetine and fluoxetine response rates were low, suggesting only modest changes in depressive symptoms. Available evidence also suggested that paroxetine and fluoxetine may be less well-tolerated than Miaserin.

The researchers reported that the alpha-2-andrenergic receptor antagonists show particular promise in treating cancer-related depression possibly due to their pharmacological profile, which increases norepinephrine and serotonin. Alpha-2-andrenergic receptor antagonists also are less likely to cause common serotonin-related side effects (headache, agitation) but may increase sedation. The researchers concluded that there is a scarcity of data on the role of antidepressants in treating cancer-related depression, and more research is needed.


Reference
Riblet N, Larson R, Watts, BV, et al.  Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. General Hospital Psychiatry, published online May 22, 2014, http://www.ghpjournal.com/article/S0163-8343(14)00116-9/abstract


Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
 
Blog Info
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN is an oncology nursing consultant and editor-in-chief of Oncology Nursing News.
Author Bio
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN, is the Editor-in-Chief for OncLive Nursing. She is an oncology nursing consultant and adjunct assistant professor of nursing at Louisiana State Health Sciences Center in New Orleans, LA. She provides continuing nursing education to nurses across the Unites States, is active in several professional nursing organizations, and is intrigued by the many ways nurses use technology to communicate.
 
 
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.